Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -26.95% as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
ALMR Return on Invested Capital (ROIC) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON INVESTED CAPITAL (ROIC)
-26.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-27.19%
median of 428 covered companies
CURRENT VS SECTOR MEDIAN
+0.88%
vs the sector median at left
Alamar Biosciences, Inc.
Market Cap
$2.64B
Return on Invested Capital (ROIC)
-26.95%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.64B
Return on Invested Capital (ROIC)
-28.96%
TTM Avg
-36.25%
3Y Avg
-29.21%
5Y Avg
-30.95%
Market Cap
$2.69B
Return on Invested Capital (ROIC)
6.69%
TTM Avg
7.54%
3Y Avg
8.48%
5Y Avg
6.84%
Market Cap
$2.69B
Return on Invested Capital (ROIC)
15.45%
TTM Avg
14.86%
3Y Avg
6.92%
5Y Avg
-8.67%
Market Cap
$2.51B
Return on Invested Capital (ROIC)
-49.78%
TTM Avg
-43.13%
3Y Avg
-47.40%
5Y Avg
-42.10%
Market Cap
$2.43B
Return on Invested Capital (ROIC)
-4.62%
TTM Avg
-19.11%
3Y Avg
-45.14%
5Y Avg
-60.93%
Market Cap
$2.87B
Return on Invested Capital (ROIC)
2.04%
TTM Avg
-4.01%
3Y Avg
-5.25%
5Y Avg
-2.96%
Market Cap
$2.87B
Return on Invested Capital (ROIC)
5.87%
TTM Avg
7.96%
3Y Avg
-0.22%
5Y Avg
-9.17%
Market Cap
$2.88B
Return on Invested Capital (ROIC)
-58.28%
TTM Avg
-46.81%
3Y Avg
-91.88%
5Y Avg
-70.41%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.64B | -26.95% | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | -28.96% | -36.25% | -29.21% | -30.95% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 6.69% | 7.54% | 8.48% | 6.84% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 15.45% | 14.86% | 6.92% | -8.67% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | -49.78% | -43.13% | -47.40% | -42.10% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.43B | -4.62% | -19.11% | -45.14% | -60.93% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 2.04% | -4.01% | -5.25% | -2.96% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 5.87% | 7.96% | -0.22% | -9.17% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -58.28% | -46.81% | -91.88% | -70.41% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | 27.60% | 29.86% | 13.68% | -0.60% |
ROIC
-26.9%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -26.95% |
